4 results about "Bacteremia" patented technology

The present application belongs to the field of microbial technology, and particularly relates to a bacteriophage preparation for controlling foodborne enterobacter and application thereof, wherein the bacteriophage preparation comprises any one or several of bacteriophage PhiEAS1, bacteriophage PhiEHO11, bacteriophage PhiEHO14 and bacteriophage PhiECL22. The four bacteriophages provided by the present application can be used alone or combined into a bacteriophage cocktail, and the influence of the bacteriophage preparation on enterobacter in different ecologies and environments is explored through bacteriophage cocktail therapy. The results show that the bacteriophage preparation exhibits significant bacteriostatic activity on various food substrates contaminated by Enterobacter hormaechei, such as lettuce, pork, milk, cherry tomato and the like; in an animal model, intraperitoneal injection of the bacteriophage preparation can effectively prevent and treat bacteremia caused by Enterobacter hormaechei, and shows potential as an anti-Enterobacter hormaechei biological control agent.

This invention relates to a Klebsiella pneumoniae mRNA molecule and its application in mRNA vaccines. This invention constructs multiple molecules encoding Klebsiella pneumoniae (… Klebsiella pneumoniae The mRNA of the antigen was extracted and its molecular sequence was optimized to ensure efficient antigen translation. The mRNA sequence is shown in any one of SEQ ID NO. 9-12. A Klebsiella pneumoniae mRNA vaccine was constructed based on a liposome nanoparticle delivery system. The mRNA vaccine can mediate a highly efficient adaptive immune response, effectively induce the activation of the Th17 / Tc17 axis in the lungs and spleen, which is beneficial to the mucosal defense and cell bactericidal mechanism of Klebsiella pneumoniae. It can establish a resident T cell memory bank in the respiratory tract, support long-term and highly effective protection, significantly reduce the risk of colonization and bacteremia, and inhibit the pro-inflammatory cascade. It also shows broad-spectrum and highly effective protection in multiple serotypes of Klebsiella pneumoniae.

This invention relates to the field of pharmaceutical synthesis technology, specifically disclosing a 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative and its general structural formula; it also discloses the preparation method and application of this derivative. This 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative exhibits good inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) and can be used to prevent and treat diseases caused by MRSA infection. Preferably, these diseases include, but are not limited to, pneumonia, urinary tract infections, bacteremia, sepsis, and suppurative arthritis caused by MRSA in humans and animals. The beneficial effects of this invention are: the 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative of this invention is obtained through a four-step reaction, the preparation method is simple, and the reaction conditions are mild; it has good inhibitory and bactericidal activity against MRSA and can be used to prevent and treat diseases caused by MRSA infection.